Yumanity Therapeutics Inc
Change company Symbol lookup
Select an option...
YMTX Yumanity Therapeutics Inc
XEVVX Eaton Vance Ltd Duration Income Fund
OTGLF CD Projekt SA
HRL Hormel Foods Corp
IPOF Social Capital Hedosophia Holdings Corp VI
NIO NIO Inc
NRT North European Oil Royalty Trust
JNJ Johnson & Johnson
STAG STAG Industrial Inc
TM Toyota Motor Corp
Go

Company profile

Yumanity Therapeutics Inc, formerly Proteostasis Therapeutics, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The platform is designed to enable the Company to screen for potential disease-modifying therapies by overcoming toxicity of misfolded proteins in neurogenerative diseases. The Company's product candidate, YTX-7739, is in Phase 1 clinical development for Parkinson's disease and YTX-9184, in IND-enabling studies for Dementia with Lewy Bodies. The Company’s pipeline consists of additional programs focused on multi- system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), frontotemporal lobar dementia (FTLD), and Alzheimer's disease.

The symbol you entered, PTI, changed to YMTX.

Price
Delayed
$20.15
Day's Change
-0.0232 (-0.12%)
Bid
--
Ask
--
B/A Size
--
Day's High
20.39
Day's Low
19.13
Volume
(Below Average)

Today's volume of 33,340 shares is on pace to be lower than YMTX's 10-day average volume of 62,854 shares.

33,340

Company Profile

Yumanity Therapeutics Inc, formerly Proteostasis Therapeutics, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The platform is designed to enable the Company to screen for potential disease-modifying therapies by overcoming toxicity of misfolded proteins in neurogenerative diseases. The Company's product candidate, YTX-7739, is in Phase 1 clinical development for Parkinson's disease and YTX-9184, in IND-enabling studies for Dementia with Lewy Bodies. The Company’s pipeline consists of additional programs focused on multi- system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), frontotemporal lobar dementia (FTLD), and Alzheimer's disease.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
--
Price/Book (MRQ)
1.42x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

December 2020
Current Month
66.6K
Previous Month
45.5K
Percent of Float
0.21%
Days to Cover
0.8342 Days

Share Information

YMTX is in a share class of common stock
Float
9.6M
Shares Outstanding
10.1M
Institutions Holding Shares
49
25.17%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • N. Anthony ColesChmn.
  • Richard PetersPres.
  • Paulash MohsenCFO
  • Marie N. EpsteinCAO
  • Benito MunozCSO

Address

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.